MOR208C310
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)
pharma · Prurigo Nodularis · Vitiligo
Incyte trial registry — 54 ClinicalTrials.gov studies with program phase, status, and indication context.
Registry index of 54 ClinicalTrials.gov studies linked to Incyte programs — each row shows trial ID, program name, phase, status, and indication.
Incyte trial registry — 54 ClinicalTrials.gov studies with program phase, status, and indication context.
Latest clinical program signals indexed for Incyte.
INCA 33989-101 — Phase 1
INCB 81776-101 — Phase 1
MOR208C310 — Phase 3
MOR208C115 — Phase 2
MK-3475-679 — Phase 3
INCMOR0208-301 — Phase 3
INCMOR 0208-305 — Phase 3
INCMGA0012-204 — Phase 2
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)
Treatment of patients with inadequately controlled moderate to severe asthma
In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.
Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies
Squamous Carcinoma of the Anal Canal
Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia